Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus

Current Drug Targets

Volumn 12, Issue 1, 2011, Pages 107-114

  Mironidou Tzouveleki, Maria ^a   Tsartsalis, Stergios ^a   Tomos, Constantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Nephropathy; Pathogenesis; Type 1 diabetes mellitus; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; GEFITINIB; IMATINIB; PEGAPTANIB; RAMUCIRUMAB; RANIBIZUMAB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ALTERNATIVE RNA SPLICING; ARTICLE; AUTOCRINE EFFECT; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PODOCYTE;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; MOLECULAR TARGETED THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78650920801     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011793591581     Document Type: Article

References (124)

1. Held PJ, Port FK, Webb RL, et al. The United States Renal Data System's 1991 annual data report: an introduction. Am J Kidney Dis 1991; 18: 1-16
2. Futrakul N, Sridama V, Futrakul P. Microalbuminuria-a biomarker of renal microvascular disease. Ren Fail 2009; 31: 140-3
3. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4: 444-52
4. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143-55
5. Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH. Glomerular structure and function in proteinuric type 2 (non- insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1064-70
6. White KE, Bilous RW. Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 2000; 11: 1667-73
7. Salmon AH, Neal CR, Harper SJ. New aspects of glomerular filtration barrier structure and function: five layers (at least) not three. Curr Opin Nephrol Hypertens 2009; 18: 197-205
8. Vaughan MR, Quaggin SE. How do mesangial and endothelial cells form the glomerular tuft? J Am Soc Nephrol 2008; 19: 24-33
9. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-1814.
10. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22
11. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660
12. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-156
13. Kretzler M, Schroppel B, Merkle M, et al. Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int Suppl 1998; 67: S159-161
14. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001; 220: 112-21
15. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down- regulated in renal cell carcinoma. Cancer Res 2002; 62: 4123-31
16. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005; 48: 2422-7
17. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-35
18. Bevan HS, van den Akker NM, Qiu Y, et al. The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol 2008; 110: p57-67
19. Simon M, Rockl W, Hornig C, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol 1998; 9: 1032-44
20. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-17
21. Cui TG, Foster RR, Saleem M, et al. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am J Physiol Renal Physiol 2004; 286: F767-73
22. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76
23. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-41
24. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311-5
25. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-9
26. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998; 241: 161-70
27. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999; 253: 117-30
28. Robert B, Zhao X, Abrahamson DR. Coexpression of neuropilin-1, Flk1, and VEGF(164) in developing and mature mouse kidney glomeruli. Am J Physiol Renal Physiol 2000; 279: F275-82
29. Harper SJ, Xing CY, Whittle C, et al. Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo. Clin Sci (Lond) 2001; 101: 439-46
30. Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transform- ing growth factor-beta1 in mouse podocytes. Diabetes 2004; 53: 2939-49
31. Thomas S, Vanuystel J, Gruden G, et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000; 11: 1236-43
32. Ku CH, White KE, Dei Cas A, et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57: 2824-33
33. Foster RR, Hole R, Anderson K, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284: F1263-73
34. Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13: 9-15
35. Miyamoto K, Kitamoto Y, Tokunaga H, et al. Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat. Lab Invest 2004; 84: 1126-36
36. Eremina V, Cui S, Gerber H, et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-35
37. Senthil D, Choudhury GG, McLaurin C, Kasinath BS. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 2003; 64: 468-79
38. Peng H, Wang C, Ye ZC, et al. How increased VEGF induces glomerular hyperpermeability: a potential signaling pathway of Rac1 activation. Acta Diabetol 2009; (In Press)
39. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 2004; 36: 1206-37
40. Monaghan-Benson E, Burridge K. The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species. J Biol Chem 2009; 284: 25602-11
41. Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 1997; 99: 2351-7
42. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-16
43. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti- VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-8
44. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58
45. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-36
46. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-93
47. Gerber HP, Wu X, Yu L, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007; 104: 3478-83
48. Advani A, Kelly DJ, Advani SL, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 2007; 104: 14448-53
49. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999; 104: 913-23
50. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000
51. Shahinian V, Rajaraman S, Borucki M, Grady J, Hollander WM, Ahuja TS. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000; 35: 884-8
52. Korgaonkar SN, Feng X, Ross MD, et al. HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 2008; 19: 877-83
53. Veron D, Reidy KJ, Bertuccio C, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 2010; 77: 989-99
54. Liu E, Morimoto M, Kitajima S, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007; 18: 2094-104
55. Schumacher VA, Jeruschke S, Eitner F, et al. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol 2007; 18: 719-29
56. Nso Roca AP, Pena Carrion A, Benito Gutierrez M, Garcia Meseguer C, Garcia Pose A, Navarro M. Evolutive study of children with diffuse mesangial sclerosis. Pediatr Nephrol 2009; 24: 1013-9
57. Ferguson J, Qiu Y, Sage LM, Neal CR, Bates DO, Harper SJ, Salmon AH. In: Ultrafiltration co-efficient in isolated intact glomeruli from podocyte-specific VEGF165b over-expressing transgenic mice. Abstracts of the 57th Meeting of the British Microcirculation Society, Belfast, UK, April 2-3 2007; British Microcirculation Society 2007
58. Klanke B, Simon M, Rockl W, Weich HA, Stolte H, Grone HJ. Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney. Nephrol Dial Transplant 1998; 13: 875-85
59. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5
60. Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008; 73: 34-42
61. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 2003; 46: 1153-60
62. Zou AP, Yang ZZ, Li PL, Cowley AW JR. Oxygen-dependent expression of hypoxia-inducible factor-1alpha in renal medullary cells of rats. Physiol Genom 2001; 6: 159-68
63. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333-40
64. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res 1995; 77: 638-43
65. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002; 290: 177-84
66. Feliers D, Kasinath BS. Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells. Mol Cell Endocrinol 2010; 314: 136-142
67. Feliers D, Gorin Y, Ghosh-Choudhury G, Abboud HE, Kasinath BS. Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. Am J Physiol Renal Physiol 2006; 290: F927-36
68. Feliers D, Duraisamy S, Barnes JL, Ghosh-Choudhury G, Kasinath BS. Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II. Am J Physiol Renal Physiol 2005; 288: F521-9
69. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30
70. Chen S, Cohen MP, Lautenslager GT, Shearman CW, Ziyadeh FN. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 2001; 59: 673-81
71. Kitamura S, Maeshima Y, Sugaya T, Sugiyama H, Yamasaki Y, Makino H. Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp Nephrol 2003; 95: e79-86
72. Menini S, Iacobini C, Oddi G, et al. Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia 2007; 50: 2591-9
73. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62: 929-39
74. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-39
75. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin- resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105: 373-9
76. Ferguson J, Sage L, Bates D, Harper S, Salmon A. In: VEGF165b reduces albuminuria and reverses increased glomerular perme- ability in animal models of diabetic nephropathy, Proceedings of the 60th Annual Meeting of the British Microcirculation Society, Peninsula Medical School, Exeter, UK, April 19-20 2010; British Microcirculation Society 2010; p. 31
77. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-34
78. Mavrakanas T, Tomos C, Mironidou-Tzouveleki M. In: Nitric oxide levels in the renal cortex of streptozocin-induced diabetic rats treated with ramipril and eplerenone. Proceedings of the 16th World Congress of Basic and Clinical Pharmacology, Copenhagen, Denmark, July 17-23, 2010; Danish Society for Pharmacology 2010; pp. 446
79. Nakagawa T. Uncoupling of VEGF with NO as a mechanism for diabetic nephropathy. Diabetes Res Clin Pract 2008; 82(Suppl 1): S67-9
80. Nakagawa T. A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism. Clin Nephrol 2009; 71: 103-9
81. Breyer MD, Bottinger E, Brosius FC 3rd, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45
82. Bailey E, Bottomley MJ, Westwell S, et al. Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. J Clin Pathol 1999; 52: 735-8
83. Grone HJ, Simon M, Grone EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995; 177: 259-67
84. Baelde HJ, Eikmans M, Lappin DW, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007; 71: 637-45
85. Lindenmeyer MT, Kretzler M, Boucherot A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007; 18: 1765-76
86. Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas CS. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus. Pediatr Res 1998; 44: 873-5
87. Chaturvedi N, Fuller JH, Pokras F, et al. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 2001; 18: 288-94
88. Dullaart RP, Oomen PH, Sluiter WJ. Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus. Eur J Intern Med 2007; 18: 193-5
89. Lenz T, Haak T, Malek J, Grone HJ, Geiger H, Gossmann J. Vascular endothelial growth factor in diabetic nephropathy. Kidney Blood Press Res 2003; 26: 338-43
90. McLaren M, Elhadd TA, Greene SA, Belch JJ. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Appl Thromb Hemost 1999; 5: 21-4
91. Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000; 17: 650-6
92. Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000; 75: S56-61
93. Seckin D, Ilhan N, Ilhan N, Ertugrul S. Glycaemic control, markers of endothelial cell activation and oxidative stress in children with type 1 diabetes mellitus. Diabetes Res Clin Pract 2006; 73: 191-7
94. Sorensen VR, Mathiesen ER, Clausen P, Flyvbjerg A, Feldt-Rasmussen B. Impaired vascular function during short-term poor glycaemic control in Type 1 diabetic patients. Diabet Med 2005; 22: 871-6
95. Santilli F, Spagnoli A, Mohn A, et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 2001; 86: 3871-6
96. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998; 94: 395-404
97. Wynendaele W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999; 10: 965-71
98. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343-50
99. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001; 47: 617-23
100. Diamant M, Hanemaaijer R, Verheijen JH, Smit JW, Radder JK, Lemkes HH. Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy. Diabet Med 2001; 18: 423-4
101. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 2009; 37: 1207-13
102. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006; 55: 1127-32
103. Satchell SC, Tooke JE. What is the mechanism of microalbu- minuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51: 714-25
104. Nowak DG, Woolard J, Amin EM, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008; 121: 3487-3495
105. Nowak DG, Amin EM, Rennel ES, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 2010; 285: 5532-5540
106. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48: 20-32
107. Tomos C MM. Vascular endothelial growth factor (VEGF) and its role in diabetic nephropathy. Epitheorese Klinikes Farmakologias kai Farmakokinetikes 2009; 27: 275-282
108. Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 2001; 280: H434-40
109. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13: 1349-1358
110. Su J, Li SJ, Chen ZH, et al. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract 2010; 87: 167-175
111. Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease. Sci World J 2009; 9: 1127-1139
112. Miyauchi M, Toyoda M, Kobayashi K, et al. Hypertrophy and loss of podocytes in diabetic nephropathy. Intern Med 2009; 48: 1615-1620
113. Osterby R, Asplund J, Bangstad HJ, et al. Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 1999; 14: 348-352
114. Osterby R, Bangstad HJ, Nyberg G, Rudberg S. On glomerular structural alterations in type-1 diabetes. Companions of early diabetic glomerulopathy. Virchows Arch 2001; 438: 129-135
115. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634
116. Foster RR. The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol 2009; 113: e8-15
117. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1- dependent mechanisms. Cancer Res 2006; 66: 3197-204
118. Korpanty G, Smyth E, Sullivan LA, Brekken RA, Carney DN. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) 2010; 235: 3-9
119. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-8
120. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10: 597-605
121. Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX. Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 2006; 17: 475-86
122. Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831-1840
123. Ichinose K, Maeshima Y, Yamamoto Y, et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 2005; 54: 2891-903
124. Kakizawa H, Itoh Y, Imamura S, et al. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist. Horm Metab Res 2004; 36: 458-464.